27 ~~26.~~ [New] The method of claim 22, wherein the shuttle plasmid is present in an amount of about fifteen times molar ratio as compared to an amount of the backbone plasmid.

28 ~~27.~~ [New] The method of claim 22, wherein the transfecting is by a calcium phosphate method of transfection.

29 ~~28.~~ [New] Ad backbone plasmid pacAd5 9.2-100, pacAd5 9.2-100/SwaI, pacAd5 9.2-100/E3Δ1.8, pacAd5 9.2-100/E3Δ2.6, pacAd5 9.2-100/E3Δ3.1, pacAd5 9.2-100/E3Δ-RSVntlacZ, pacAd5 9.2-100/E3Δ-RSVEGFP, pacAd5 9.2-100/E4Δ, pacAd5 9.2-100/E3ΔE4orf6, or pacAd5 9.2-100/E3CMVmcspA.

30 ~~29.~~ [New] A cloning system for generating recombinant adenovirus comprising:

(a) Ad backbone plasmid pacAd5 9.2-100, pacAd5 9.2-100/SwaI, pacAd5 9.2-100/E3Δ1.8, pacAd5 9.2-100/E3Δ2.6, pacAd5 9.2-100/E3Δ3.1, pacAd5 9.2-100/E3Δ-RSVntlacZ, pacAd5 9.2-100/E3Δ-RSVEGFP, pacAd5 9.2-100/E4Δ, pacAd5 9.2-100/E3ΔE4orf6, or pacAd5 9.2-100/E3CMVmcspA, and

(b) a shuttle plasmid comprising Ad sequences from 0 to 1 map units and 9.2 to 16.1 map units of an Ad genome.

29 contd.

31 ~~30.~~ [New] A host cell comprising:

(a) Ad backbone plasmid pacAd5 9.2-100, pacAd5 9.2-100/SwaI, pacAd5 9.2-100/E3Δ1.8, pacAd5 9.2-100/E3Δ2.6, pacAd5 9.2-100/E3Δ3.1, pacAd5 9.2-100/E3Δ-RSVntlacZ, pacAd5 9.2-100/E3Δ-RSVEGFP, pacAd5 9.2-100/E4Δ, pacAd5 9.2-100/E3ΔE4orf6, or pacAd5 9.2-100/E3CMVmcspA, and

(b) a shuttle plasmid comprising Ad sequences from 0 to 1 map units and 9.2 to 16.1 map units of an Ad genome.

32 ~~31.~~ [New] The host cell of claim 30, wherein the cell is an animal cell.

33. [New] A method for producing recombinant adenovirus comprising contacting a host cell with

(a) Ad backbone plasmid pacAd5 9.2-100, pacAd5 9.2-100/SwaI, pacAd5 9.2-100/E3Δ1.8, pacAd5 9.2-100/E3Δ2.6, pacAd5 9.2-100/E3Δ3.1, pacAd5 9.2-100/E3Δ-RSVntlacZ, pacAd5 9.2-100/E3Δ-RSVEGFP, pacAd5 9.2-100/E4Δ, pacAd5 9.2-100/E3ΔE4orf6, or pacAd5 9.2-100/E3CMVmcspA, and

(b) a shuttle plasmid comprising Ad sequences from 0 to 1 map units and 9.2 to 16.1 map units of an Ad genome.

34. [New] The method of claim 32, further comprising serially amplifying virus produced by the host cell.

35. [New] The method of claim 32, further comprising detecting the presence of wild type virus.

REMARKS

Applicant has carefully reviewed and considered the Advisory Action mailed on October 21, 2002. Claim 22 has been amended, claims 2-8, 10-21, and 23-25 have been cancelled, and claims 26-34 are newly added. As a result, claims 22 and 26-34 are now pending in this application. No new subject matter has been added. The amendments are made to clarify the claims, and not for reasons relating to patentability. Therefore, the amendments are not intended to limit the scope of equivalents to which any claim element may be entitled.

Support for the amendment to claim 22 is found throughout the specification, for example on page 6, lines 12-13. Support for new claim 26 is found throughout the specification, for example on page 5, line 7. Support for new claim 27 is found throughout the specification, for example on page 11, lines 27-28. Support for new claims 28-34 is found throughout the specification, for example in the originally-filed claims, and in the specification at pages 8-11.